Although anti-IL-17 and anti-IL-17 receptor antibodies are effective for psoriasis (53, 54), the blockade of TL1A-DR3 interaction can also be an alternative therapeutic approach by repressing IL-22 overproduction. Here, TNFRSF25 is linked to psoriasis.